Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Voyager Therapeutics (VYGR) FCF Margin (2016 - 2025)

Historic FCF Margin for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to 233.25%.

  • Voyager Therapeutics' FCF Margin fell 1186400.0% to 233.25% in Q3 2025 from the same period last year, while for Sep 2025 it was 378.79%, marking a year-over-year decrease of 3613000.0%. This contributed to the annual value of 23.54% for FY2024, which is 534000.0% down from last year.
  • According to the latest figures from Q3 2025, Voyager Therapeutics' FCF Margin is 233.25%, which was down 1186400.0% from 660.88% recorded in Q2 2025.
  • Voyager Therapeutics' 5-year FCF Margin high stood at 5197.26% for Q1 2022, and its period low was 2743.96% during Q2 2022.
  • In the last 5 years, Voyager Therapeutics' FCF Margin had a median value of 114.6% in 2024 and averaged 120.0%.
  • Per our database at Business Quant, Voyager Therapeutics' FCF Margin skyrocketed by 55305800bps in 2022 and then tumbled by -51154900bps in 2023.
  • Voyager Therapeutics' FCF Margin (Quarter) stood at 38.64% in 2021, then surged by 2100bps to 850.13% in 2022, then crashed by -103bps to 27.22% in 2023, then crashed by -759bps to 233.9% in 2024, then grew by 0bps to 233.25% in 2025.
  • Its last three reported values are 233.25% in Q3 2025, 660.88% for Q2 2025, and 593.12% during Q1 2025.